The South Florida Business Journal reported on the boom in compounded GLP-1s and Scott explained why the threat of (baseless) lawsuits from pharma companies can keep some pharmacists from talking about it.
Bonus: Both Eli Lilly and Novo Nordisk admitted to threatening compounders even without legal basis.